Hedan tablet ameliorated non‐alcoholic steatohepatitis by moderating NF‐κB and lipid metabolism‐related pathways via regulating hepatic metabolites. The gene discussed is NFKB1; the disease is metabolic dysfunction-associated steatohepatitis.